CYP3A4 and non-small cell lung carcinoma: The intended target population of tepotinib is patients with advanced or metastatic NSCLC, who are mostly elderly and often receive multiple concomitant drugs including drugs that are metabolized by CYP3A4 or transported by P-pg.